Quarterly ResultMay 5, 2026, 04:09 PM
Integra LifeSciences Q1 Revenue $391.9M; Net Loss Narrows to $4.6M
AI Summary
Integra LifeSciences reported Q1 2026 net revenue of $391.9 million, an increase from $382.7 million in Q1 2025. The company significantly narrowed its net loss to $4.6 million, or $(0.06) per share, compared to a net loss of $25.3 million, or $(0.33) per share, in the prior year period. Additionally, Integra LifeSciences recognized an $18.7 million receivable for IEEPA tariff refunds and detailed an amendment to its Senior Credit Facility in June 2025, which modified Consolidated Total Leverage Ratio covenants. The company also updated its segment names to Specialty Surgery and Tissue Reconstruction.
Key Highlights
- Net revenue increased to $391.9 million in Q1 2026 from $382.7 million in Q1 2025.
- Net loss significantly narrowed to $4.6 million, or $(0.06) per share, in Q1 2026.
- Operating income turned positive at $11.5 million in Q1 2026, from a $(15.5) million loss in Q1 2025.
- Recognized an $18.7 million receivable for IEEPA tariff refunds in Q1 2026.
- Net cash provided by operating activities was $9.8 million, compared to $(11.3) million used in Q1 2025.
- Specialty Surgery segment revenue rose to $283.1 million from $280.7 million year-over-year.
- Tissue Reconstruction segment revenue increased to $108.8 million from $102.0 million year-over-year.
- Total current liabilities decreased to $346.8 million at March 31, 2026, from $456.0 million at December 31, 2025.
Price Impact
More from IART